Treatsma website reaches national news in Bhutan.

We are pleased to share with you the initiation of MANATEE, a new global Phase 2/3 clinical study that aims to evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth in combination with risdiplam, in Spinal Muscular Atrophy (SMA).

We are pleased to share with you the initiation of MANATEE, a new global Phase 2/3 clinical study that aims to evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth in combination with risdiplam, in Spinal Muscular Atrophy (SMA).

TreatSMA Trustee Andi Thornton speaks with SMA UK Trustee Toby Mildon about mental health, treatments, University and work, health care and much more

TreatSMA Trustee Andi Thornton speaks with SMA UK Trustee Toby Mildon about mental health, treatments, University and work, health care and much more

New Clinical Study Planned to Evaluate the Potential Benefit of an Investigational Higher Dose of Nusinersen in People with SMA Previously Treated with Evrysdi® (risdiplam)

New Clinical Study Planned to Evaluate the Potential Benefit of an Investigational Higher Dose of Nusinersen in People with SMA Previously Treated with Evrysdi® (risdiplam)

SMA UK has put out a community survey asking for people’s views on what services and activities they should focus on in the future. You can respond to their survey here https://www.surveymonkey.co.uk/r/SMAUKnext